G. Bianchini, J. M. Balko, I. A. Mayer, S. Me, and L. Gianni, Triple-negative breast cancer: challenges and opportunities of a heteroge

, Effect of bi-daily subcutaneous administration of 0.5 mg/kg homoharringtonine over 7 days on MDA-MB-468 xenografts in mice. A and B: Tumor volumes, absolute values. C: Tumor volume before and after treatment, mean ± SD. D and E: Mouse weight

H. Hht,

, Am J Cancer Res, vol.9, issue.5, pp.1043-1060, 2019.

, Nat Rev Clin Oncol, vol.13, pp.674-690, 2016.

M. V. Dieci, E. Orvieto, M. Dominici, P. Conte, and V. Guarneri, Rare breast cancer subtypes: histological, molecular, and clinical peculiarities, Oncologist, vol.19, pp.805-813, 2014.

K. K. Thakur, D. Bordoloi, and A. B. Kunnumakkara, Alarming burden of triple-negative breast cancer in India, Clin Breast Cancer, vol.18, pp.393-399, 2018.

J. H. Park, J. H. Ahn, and S. B. Kim, How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies, ESMO Open, vol.3, p.357, 2018.

C. Liedtke, C. Mazouni, K. R. Hess, F. Andre, A. Tordai et al., Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J Clin Oncol, vol.26, pp.1275-1281, 2008.

P. Khosravi-shahi, C. , C. , and S. , Metastatic triple negative breast cancer: optimizing treatment options, new and emerging targeted therapies, Asia Pac J Clin Oncol, vol.14, pp.32-39, 2018.

F. Kassam, K. Enright, R. Dent, G. Dranitsaris, J. Myers et al., Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design, Clin Breast Cancer, vol.9, pp.29-33, 2009.

F. Alvandi, V. E. Kwitkowski, C. W. Ko, M. D. Rothmann, S. Ricci et al., S. food and drug administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia, Oncologist, vol.19, pp.94-99, 2014.

S. Lu and J. Wang, Homoharringtonine and omacetaxine for myeloid hematological malignancies, J Hematol Oncol, vol.7, issue.2, 2014.

W. Cao, Y. Liu, R. Zhang, B. Zhang, T. Wang et al., Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells, Sci Rep, vol.5, p.8477, 2015.

T. Y. Weng, H. F. Wu, C. Y. Li, Y. H. Hung, Y. W. Chang et al., Homoharringtonine induced immune alteration for an efficient anti-tumor response in mouse models of non-small cell lung adenocarcinoma expressing Kras mutation, Sci Rep, vol.8, p.8216, 2018.

R. M. Tujebajeva, D. M. Graifer, G. G. Karpova, and N. A. Ajtkhozhina, Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation, FEBS Lett, vol.257, pp.254-256, 1989.

M. Bhat, N. Robichaud, L. Hulea, N. Sonenberg, J. Pelletier et al., Targeting the translation machinery in cancer, Nat Rev Drug Discov, vol.14, pp.261-278, 2015.

V. Gandhi, W. Plunkett, and J. E. Cortes, Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia, Clin Cancer Res, vol.20, pp.1735-1740, 2014.

C. Vaklavas, S. W. Blume, and W. E. Grizzle, Translational dysregulation in cancer: molecular insights and potential clinical applications in biomarker development, Front Oncol, vol.7, p.158, 2017.

L. M. Lindqvist, K. Tandoc, I. Topisirovic, and L. Furic, Cross-talk between protein synthesis, energy metabolism and autophagy in cancer, Curr Opin Genet Dev, vol.48, pp.104-111, 2018.

G. Liao, L. Mingle, L. Van-de-water, and G. Liu, Control of cell migration through mRNA localization and local translation, Wiley Interdiscip Rev RNA, vol.6, pp.1-15, 2015.

P. N. Kelly and A. Strasser, The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy, Cell Death Differ, vol.18, pp.1414-1424, 2011.

T. Okamoto, L. Coultas, D. Metcalf, M. F. Van-delft, S. P. Glaser et al., Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis, Proc Natl Acad Sci U S A, vol.111, pp.261-266, 2014.

K. J. Campbell, S. Dhayade, N. Ferrari, A. H. Sims, J. E. Mason et al., MCL-1 is a prognostic indicator and drug target in breast cancer, Cell Death Dis, vol.9, p.19, 2018.

C. M. Goodwin, O. W. Rossanese, E. T. Olejniczak, and S. W. Fesik, Myeloid cell leukemia-1 is an important apoptotic survival factor in triplenegative breast cancer, Cell Death Differ, vol.22, pp.2098-2106, 2015.

J. M. Balko, J. M. Giltnane, K. Wang, L. J. Schwarz, C. D. Young et al., Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets, Cancer Discov, vol.4, pp.232-245, 2014.

S. Z. Millis, Z. Gatalica, J. Winkler, S. Vranic, J. Kimbrough et al., Predictive biomarker profiling of > 6000 breast cancer patients shows heterogeneity in TNBC, with treatment implications, Clin Breast Cancer, vol.15, pp.473-481, 2015.

M. R. Warr and G. C. Shore, Unique biology of Mcl-1: therapeutic opportunities in cancer, Curr Mol Med, vol.8, pp.138-147, 2008.

K. Doi, R. Li, S. S. Sung, H. Wu, Y. Liu et al., Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation, J Biol Chem, vol.287, pp.10224-10235, 2012.

A. Kotschy, Z. Szlavik, J. Murray, J. Davidson, A. L. Maragno et al., The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models, Nature, vol.538, pp.477-482, 2016.

C. L. Fletcher and S. , Mcl-1 inhibitors: a patent review, Expert Opin Ther Pat, vol.27, pp.163-178, 2017.

R. Tang, A. M. Faussat, P. Majdak, C. Marzac, S. Dubrulle et al., Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells, Mol Cancer Ther, vol.5, pp.723-731, 2006.

J. Kuroda, Y. Kamitsuji, S. Kimura, E. Ashihara, E. Kawata et al., Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin, Int J Hematol, vol.87, pp.507-515, 2008.

R. Chen, L. Guo, Y. Chen, Y. Jiang, W. G. Wierda et al., Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia, Blood, vol.117, pp.156-164, 2011.

B. D. Lehmann, J. A. Bauer, X. Chen, M. E. Sanders, A. B. Chakravarthy et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, vol.121, pp.2750-2767, 2011.

J. Gioanni, L. Francois, D. Zanghellini, E. Mazeau, C. Ettore et al., Establishment and characterisation of a new tumorigenic cell line with a normal karyotype derived from a human breast adenocarcinoma, Br J Cancer, vol.62, pp.8-13, 1990.

A. El-guerrab, M. Bamdad, Y. J. Bignon, F. Penault-llorca, and C. Aubel, Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTENwild-type triple-negative breast cancer cells

, Mol Carcinog, vol.56, pp.1383-1394, 2017.

T. C. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol Rev, vol.58, pp.621-681, 2006.

V. Levy, S. Zohar, C. Bardin, A. Vekhoff, D. Chaoui et al., A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia, Br J Cancer, vol.95, pp.253-259, 2006.

J. T. Opferman, Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members, FEBS J, vol.283, pp.2661-2675, 2016.

S. R. Hann, C. B. Thompson, and R. N. Eisenman, cmyc oncogene protein synthesis is independent of the cell cycle in human and avian cells, Nature, vol.314, pp.366-369, 1985.

K. M. Lee, J. M. Giltnane, J. M. Balko, L. J. Schwarz, A. L. Guerrero-zotano et al., Fesik SW and Arteaga CL. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation, Cell Metab, vol.26, p.637, 2017.

T. P. Zhao, G. X. Ding, H. Y. Gao, Z. Z. Shen, and K. Y. Li, A clinical trial of homoharringtonine in the treatment of advanced breast cancer, Tumori, vol.72, pp.395-398, 1986.

J. A. Ajani, I. Dimery, S. P. Chawla, K. Pinnamaneni, R. S. Benjamin et al., Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas, Cancer Treat Rep, vol.70, pp.375-379, 1986.

W. Chen, H. Wang, M. Cheng, L. Ni, L. Zou et al., Isoharringtonine inhibits breast cancer stem-like properties and STAT3 signaling, Biomed Pharmacother, vol.103, pp.435-442, 2018.

L. Li, L. J. Xia, J. C. Han, and R. , Induction of apoptosis by harringtonine and homoharri, Am J Cancer Res, vol.9, issue.5, pp.1043-1060, 2019.

, Yao Xue Xue Bao, vol.29, pp.667-672, 1994.

L. Yinjun, J. Jie, X. Weilai, and T. Xiangming, Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP), Am J Hematol, vol.76, pp.199-204, 2004.

L. Marenah, E. K. Allan, J. C. Mountford, T. L. Holyoake, H. G. Jorgensen et al., Investigation into omacetaxine solution stability for in vitro study, Biomed Chromatogr, vol.26, pp.545-547, 2012.

J. Nemunaitis, A. Mita, J. Stephenson, M. M. Mita, J. Sarantopoulos et al., Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors, Cancer Chemother Pharmacol, vol.71, pp.35-41, 2013.

D. Merino, J. R. Whittle, F. Vaillant, A. Serrano, J. N. Gong et al., Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer, Sci Transl Med, vol.9, 2017.

E. K. Allan, T. L. Holyoake, A. R. Craig, and H. G. Jorgensen, Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells, Leukemia, vol.25, pp.985-994, 2011.

M. Li, F. Shi, X. Fei, S. Wu, D. Wu et al., PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells, Exp Biol Med (Maywood), vol.242, pp.996-1004, 2017.

S. Yin, V. T. Cheryan, L. Xu, A. K. Rishi, and K. B. Reddy, Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells, PLoS One, vol.12, p.183578, 2017.